Home ••• Newswires by Industry • Countries • U.S. States • World Media Directory

Pharmaceutical Industry News ••• Topics • Countries • U.S. States

Ovarian Cancer Drugs News Monitoring

Get by Email • RSS

Published on 03:24 GMT

Nemvaleukin Alfa Development Halted in Ovarian Cancer

The combination of nemvaleukin alfa (ALKS 4230) and pembrolizumab (Keytruda) did not achieve a statistically significant improvement in overall survival (OS) vs investigator’s choice of chemotherapy in the phase 3 ARTISTRY-7 trial (NCT05092360) for …

Source: Targeted Oncology - Label Pending
Published on 01:03 GMT

Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57%

Mural Oncology is discontinuing the development of nemvaleukin alfa in ovarian cancer after a Phase III trial failed to improve overall survival (OS) in platinum-resistant ovarian cancer (PROC), prompting a 57% drop in stock value. The US company announced …

Source: Clinical Trials Arena - Label Pending
Published on Mar 25, 2025

ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy

As patients receive “more and more lines of therapy”, their likelihood of responding to treatment falls, according to Elizabeth Lee, MD. After delivering a presentation on the phase 1/2 RAINFOL-01 trial (NCT05579366) at the 2025 Society of Gynecologic …

Source: Cancer Network - New Jersey - Label Pending
Published on 00:19 GMT

Mural Oncology sinks on nemvaleukin miss in ovarian cancer

Losing nearly 60% of its value, Mural Oncology plc backed away from its lead interleukin-2 (IL-2) drug, nemvaleukin alfa, in platinum-resistant ovarian cancer based on interim results showing it failed to reach significance in the overall survival primary …

Source: BioWorld - Label Pending
Published on Mar 25, 2025

Nemvaleukin Fails to Show OS Benefit Over Chemotherapy in Platinum-Resistant Ovarian Cancer

Based on data from the prespecified interim analysis of the phase 3 ARTISTRY-7 trial (NCT05092360), which failed to show a statistically significant improvement in overall survival (OS) with nemvaleukin alfa (ALKS 4230; nemvaleukin) in combination with …

Source: OncLive - Label Pending
Published on Mar 25, 2025

Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer

Treatment-emergent ocular events (TEOEs) in patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer treated with mirvetuximab soravtansine (Elahere; AbbVie) during the phase 3 MIRASOL (NCT04209855) trial were not …

Source: The American Journal of Managed Care - Neutral
Published on Mar 25, 2025

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment

Imunon has announced the alignment of the US Food and Drug Administration (FDA) with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol. IMNN-001, the company’s lead candidate, is being developed for treating women with newly diagnosed …

Source: Clinical Trials Arena - Label Pending
Published on Mar 25, 2025

Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer

Innovent Biologics, Inc, a world-class biopharmaceutical company, announces that the first participant has been successfully dosed with IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) in a randomized, controlled, multicenter …

Source: Pharmabiz.com - Neutral
Published on Mar 25, 2025

Mural To Not Progress Platinum-Resistant Ovarian Cancer Trial To Final Analysis, Stock Down

Mural Oncology plc (MURA), Tuesday announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck's (MRK) Keytruda in patients with platinum-resistant ovarian cancer will not progress to final analysis. The decision comes as …

Source: RTTNews - Neutral
Published on Mar 25, 2025

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s unwavering commitment to patient impact, “Breaking …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on Mar 25, 2025

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for broad …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on Mar 25, 2025

Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges

On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc’s MRK Keytruda (pembrolizumab) vs. investigator choice single agent chemotherapy for platinum-resistant ovarian …

Source: Benzinga - Neutral
Published on Mar 25, 2025

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) ...

Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability profile generally consistent with previously reported data; …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on Mar 25, 2025

Expanding HRD and BRCA1/2 Testing Could Improve Access to Effective Treatments in Ovarian and Breast Cancer

Increased testing to identify patients with homologous repair deficiency (HRD)-negative or BRCA1/2-positive tumors could expand access to targeted treatments such as PARP inhibitors for those with epithelial ovarian cancer (EOC) or metastatic breast …

Source: Targeted Oncology - Label Pending
Published on Mar 25, 2025

Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer

Elizabeth Lee, MD, presented results from dose expansion cohort B1 of the phase 1/2 RAINFOL-01 trial (NCT05579366) at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO) that found rinatabart sesutecan (Rina-S) elicited “ …

Source: Cancer Network - New Jersey - Label Pending
Published on Mar 25, 2025

When a Cancer Drug Shortens Life: Lessons From ARIEL4

Something unprecedented happened in a recent phase 3 trial: Patients were significantly harmed by an experimental cancer drug. This is not something we see often in oncology, where either overall survival does not improve or, when the experimental drug …

Source: Medscape - Neutral
Published on Mar 24, 2025

Innovent Biologics doses first subject in trial of ovarian cancer therapy

Innovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating platinum-resistant ovarian cancer (PROC) with human epidermal growth factor receptor 2 (HER2) expression. This multicentre trial …

Source: Clinical Trials Arena - Label Pending
Published on Mar 24, 2025

First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer

The first patient has been successfully dosed with IBI354 in the phase 3 clinical trial HeriCare-Ovarian01 for patients with platinum-resistant ovarian cancer and HER2 expression, according to the drug’s manufacturer, Innovent Biologics, Inc. " …

Source: Cure Today - Neutral
Published on Mar 24, 2025

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer

The Food and Drug Administration (FDA), with Imunon Inc., has finalized the study design for the phase 3 OVATION 3 clinical trial evaluating IMNN-001 among patients with newly diagnosed advanced ovarian cancer, according to a pree release from the company. …

Source: Cure Today - Neutral

05 days 21:16:08

Featured Releases

Got News to Share? · Submit · See All

Published on March 25, 2025 - 13:44 GMT

Dermatological Drugs Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

The Business Research Company’s Dermatological Drugs Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, March 25, 2025 /⁨EINPresswire.com⁩/ -- The unveiling of the dermatological drugs global …

Distribution channels: Business & Economy, Chemical Industry ...
Published on March 25, 2025 - 14:09 GMT

Top Growth Driver In The Chromatography Instrumentations Market 2025: Impact Of The Growing Pharmaceutical Industry

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today! LONDON, GREATER LONDON, UNITED KINGDOM, March 25, 2025 /⁨EINPresswire.com⁩/ -- Did you know that the chromatography instrumentations …

Distribution channels: Business & Economy, Companies ...

Published on March 25, 2025 - 23:00 GMT

Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research ...

ROCKVILLE, Md. and SUZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 15:25 GMT

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced …

Distribution channels: Business & Economy, Companies ...

Published on March 25, 2025 - 15:23 GMT

Cholinesterase Che Inhibitors Global Market Report 2025: A Comprehensive Overview Of Emerging Trends And Growing

Enjoy a flat 15% OFF on all 2025 Global Market Reports until March 31st! Use code FY25SAVE to save big—don’t miss out! LONDON, GREATER LONDON, UNITED KINGDOM, March 26, 2025 /⁨EINPresswire.com⁩/ -- The year 2024 saw the cholinesterase ChE …

Distribution channels: Business & Economy, Companies ...
Published on March 25, 2025 - 20:40 GMT

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for broad …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 20:30 GMT

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 20:01 GMT

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical …

Distribution channels:

Got news to share? Submit it now.

Load more pharmaceuticals news or search news using your own keywords. There are 797,200,670 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country

Pharmaceutical Industry News by U.S. State

Pharmaceutical Industry News Topics

Online News Publications

World News Report

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter

Create RSS Feed

NewsPlugin for WordPress

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire

Events

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 03/19/2025

World Media Directory

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All

Published on March 26, 2025 - 06:21 GMT

Sister2Sister and Unite Genomics Partner to Enhance Breast Cancer Care for Minority and Underserved Communities

The partners will leverage AI to help breast cancer patients navigate care, address treatment gaps, and improve outcomes SOMERSET, NJ, UNITED STATES, March 26, 2025 /⁨EINPresswire.com⁩/ -- Sister2Sister, a leading breast cancer survivorship …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 26, 2025 - 06:00 GMT

New Book Navigating Inflammatory Bowel Disease – A Six-Week Blueprint for Better Gut Health

Empowers Patients and Caregivers ST PETERSBURG, FL, UNITED STATES, March 26, 2025 /⁨EINPresswire.com⁩/ -- New Book Navigating Inflammatory Bowel Disease – A Six-Week Blueprint for Better Gut Health Empowers Patients and Caregivers Today marks the launch …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 26, 2025 - 05:28 GMT

Avotres Inc. Founder and CSO, Dr. Hong Jiang Presented at the 7th Treg-Directed Therapies Summit

BOSTON, MA, UNITED STATES, March 26, 2025 /⁨EINPresswire.com⁩/ -- Avotres proudly announces the successful presentation, titled as “Analyzing the Q/E CD8+ Treg Pathway to Unlock Effective Clinical Applications: Q/E CD8+Treg Pathway Directed …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
Published on March 26, 2025 - 05:01 GMT

Global Guillain Barre Syndrome Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034

The Business Research Company's Guillain-Barre Syndrome Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, March 26, 2025 /⁨EINPresswire.com⁩/ -- Updated 2025 Market Reports …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
Published on March 26, 2025 - 05:01 GMT

In-Depth Analysis Of The Global Growth Hormone Deficiency Market: Key Drivers, Trends, Growth And Forecast 2025-2034

The Business Research Company's Growth Hormone Deficiency Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, March 26, 2025 /⁨EINPresswire.com⁩/ -- Updated 2025 Market Reports …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
Published on March 26, 2025 - 00:13 GMT

Infinnium Launches BECProfiler™: A Cutting-Edge Solution to Automate Business Email Compromise Investigations

Business Email Compromise Investigations are time consuming, manual, and costly. BECProfiler™ reduces the time to minutes and lowers cost. CHANTILLY, VA, UNITED STATES, March 26, 2025 /⁨EINPresswire.com⁩/ -- Infinnium, a leader in AI-driven data …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
Published on March 26, 2025 - 00:00 GMT

Next Featured Solution Provider for Mostly Medicaid StarSearch Series: Rosarium Health (Show date- April 18th, 2025)

The next installment of Medicaid StarSearch features Rosarium Health founder Cameron Carter and his vision to unlock the home modification benefit for members. BIRMINGHAM, AL, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- MostlyMedicaid …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 26, 2025 - 00:00 GMT

C&F Plumbing Expands with New Location in Mountain Lakes, NJ

C&F Plumbing, serving North Jersey since 2009, expands to Mountain Lakes to better serve Morris and Sussex Counties with expert plumbing services. SPARTA, NJ, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- C&F Plumbing, a trusted …

Distribution channels: Business & Economy, Companies ...
Published on March 25, 2025 - 21:58 GMT

HeartLung Technologies welcomes medical imaging and bioengineering expert Dr. Zahi A. Fayad, PHD, to the Advisory Board

HeartLung Technologies proudly announces Dr. Zahi A. Fayad, PhD, joining the advisory board to enhance AI-driven preventive healthcare solutions. HOUSTON, TX, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- HeartLung Technologies is proud to …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...
Published on March 25, 2025 - 21:00 GMT

Blueberries Medical Announces C$1 Million Non-Brokered Private Placement

Blueberries secures C$1.05M in private placement led by Terraflos to fund expansion and operations across Latin America. Blueberries Medical Corp (OTCMKTS:BBRRF) TORONTO, ONTARIO, CANADA, March 25, 2025 /⁨EINPresswire.com⁩/ -- Blueberries Medical …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 21:00 GMT

GO2 for Lung Cancer Forms the Global Advisory Council to Support Its Mission to Confront Lung Cancer

WASHINGTON, DC, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- GO2 for Lung Cancer (GO2) announced it established the Global Advisory Council (GAC), a new group that brings together scientists, medical specialists, and other healthcare …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 20:45 GMT

Accessia Health to Host Free Medicare Part D Webinar; Highlight New Survey Data on What is Working and What Needs Fixing

Educational gap may persist for Medicare recipients and caregivers; over half don’t recall receiving any information on new cost savings plan MIDLOTHIAN, VA, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- What: Join patient advocates, …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 20:27 GMT

Robot Industries Launches RiA Agents AI: A Game-Changer in Intelligent Automation

Robot Industries introduces RiA AI agents to revolutionize business automation and enhance human potential! BERLIN, GERMANY, March 25, 2025 /⁨EINPresswire.com⁩/ -- Robot Industries is proud to announce the launch of RiA - AI Agents for Business …

Distribution channels: Automotive Industry, Banking, Finance & Investment Industry ...
Published on March 25, 2025 - 20:00 GMT

CloudAtlas AI Guardian Now Available on Microsoft Azure Marketplace

UnifyCloud protects your AI investments with CloudAtlas AI Guardian, now accessible on Microsoft Azure Marketplace for secure and responsible AI integration. REDMOND, WA, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- UnifyCloud, a global …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
Published on March 25, 2025 - 19:32 GMT

Singota Solutions Expands European Footprint to 3 Sites, Adds New State-of-the-Art Facility in Balerna, Switzerland

Singota Solutions expands in Europe with new GDP-certified Balerna, Switzerland site, offering bonded warehousing & cold storage for pharma logistics. BLOOMINGTON, IN, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- Singota Solutions, a …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 19:21 GMT

Titan Health Launches Groundbreaking Revenue Cycle Management as a Service (RCMaaS)

Innovative Offering Combines AI and Industry-Leading RCM Practices to Set New Benchmarks TUCSON, AZ, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- Titan Health, a pioneer in high-performance revenue cycle management (RCM) services for the …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 19:15 GMT

PathFree Technologies Joins Octane's LaunchPad SBDC Accelerator Program, Prepares for High-Stakes Fast Pitch Event

PathFree Technologies joins Octane’s LaunchPad SBDC Accelerator, preparing to pitch AI-driven healthcare solutions to top VCs and investors at Fast Pitch. IRVINE, CA, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- PathFree Technologies …

Distribution channels: Business & Economy, Emergency Services ...
Published on March 25, 2025 - 18:38 GMT

Pleasanton Children’s Dentistry & Braces Unveils New State-of-the-Art Facility to Better Serve the Community

Pleasanton Children’s Dentistry & Braces opens a new building, expanding care to meet the growing needs of Pleasanton and surrounding areas. PLEASANTON, TX, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- Pleasanton Children’s Dentistry …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 18:37 GMT

Safari Children’s Dentistry & Braces Celebrates Grand Opening of New Facility

Safari Children’s Dentistry & Braces opens a state-of-the-art facility, enhancing pediatric dental care for the San Antonio community. SAN ANTONIO, TX, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- Safari Children's Dentistry & …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on March 25, 2025 - 18:37 GMT

Sunshine Pediatric Dentistry and Orthodontics Introduces a Specialty Boutique Store for Enhanced Dental Care Experience

Sunshine Pediatric Dentistry and Orthodontics unveils a specialty boutique store, offering a unique and enhanced dental care experience for patients. SAN ANTONIO, TX, UNITED STATES, March 25, 2025 /⁨EINPresswire.com⁩/ -- Sunshine Pediatric …

Distribution channels: Healthcare & Pharmaceuticals Industry ...